FGFR4 Gene Fusions clinical trials at UCSF
1 research study open to eligible people
Fgfr4 gene fusions join the FGFR4 gene to other genes and can change cell signals. UCSF is studying a drug's safety and side effects in people with these genetic changes. UCSF is tracking early evidence of tumor response and safe dose ranges.
Showing trials for
Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
open to eligible people ages 18 years and up
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
San Francisco, California and other locations
Last updated: